Pembrolizumab as a treatment for PML?
Waiting for Godot
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published October 9, 2019.
Author Disclosures
- Renaud A. Du Pasquier, MD
- Renaud A. Du Pasquier, MD
Merck, Celgene, Sanofi
NONE
Celgene, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swiss National Foundation 320030-179531 Swiss Society for Multiple Sclerosis
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, University of Lausanne, Switzerland.
- Correspondence
Dr. Du Pasquier renaud.du-pasquier{at}chuv.ch
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang